Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

A Monte Carlo Method for Determining the Response Relationship between Two Commonly Used Detectors to Indirectly Measure Alpha Particle Radiation Activity.

Tichacek CJ, Budzevich MM, Wadas TJ, Morse DL, Moros EG.

Molecules. 2019 Sep 19;24(18). pii: E3397. doi: 10.3390/molecules24183397.

2.

Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.

Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalani NI, El-Haddad G, Triozzi PL, Moros EG, McLaughlin ML, Wadas TJ, Morse DL.

J Nucl Med. 2019 Aug;60(8):1124-1133. doi: 10.2967/jnumed.118.217240. Epub 2019 Feb 7.

PMID:
30733316
3.

Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway.

Khabibullin AR, Karolak A, Budzevich MM, McLaughlin ML, Morse DL, Woods LM.

Medchemcomm. 2018 Jun 6;9(7):1155-1163. doi: 10.1039/c8md00170g. eCollection 2018 Jul 1.

4.

Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling.

Karolak A, Estrella VC, Huynh AS, Chen T, Vagner J, Morse DL, Rejniak KA.

Sci Rep. 2018 Feb 26;8(1):3638. doi: 10.1038/s41598-018-21883-z.

5.

Cell-surface marker discovery for lung cancer.

Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, Zhou JM, Boulware DC, Kim J, Haura EB, Morse DL.

Oncotarget. 2017 Dec 7;8(69):113373-113402. doi: 10.18632/oncotarget.23009. eCollection 2017 Dec 26.

6.

The Damaging Effect of Passenger Mutations on Cancer Progression.

McFarland CD, Yaglom JA, Wojtkowiak JW, Scott JG, Morse DL, Sherman MY, Mirny LA.

Cancer Res. 2017 Sep 15;77(18):4763-4772. doi: 10.1158/0008-5472.CAN-15-3283-T. Epub 2017 May 23.

7.

The channel capacity of visual awareness divided among multiple moving objects.

Lappin JS, Morse DL, Seiffert AE.

Atten Percept Psychophys. 2016 Nov;78(8):2469-2493.

PMID:
27357842
8.

Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.

Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I, Mintz A, Li KC, Wadas TJ.

Theranostics. 2016 Mar 1;6(5):698-709. doi: 10.7150/thno.14338. eCollection 2016.

9.

Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue.

Roy J, Putt KS, Coppola D, Leon ME, Khalil FK, Centeno BA, Clark N, Stark VE, Morse DL, Low PS.

Oncotarget. 2016 Mar 22;7(12):14605-15. doi: 10.18632/oncotarget.7522.

10.

Cell-surface markers for colon adenoma and adenocarcinoma.

Sewda K, Coppola D, Enkemann S, Yue B, Kim J, Lopez AS, Wojtkowiak JW, Stark VE, Morse B, Shibata D, Vignesh S, Morse DL.

Oncotarget. 2016 Apr 5;7(14):17773-89. doi: 10.18632/oncotarget.7402.

11.

Chromosome-Specific and Global Effects of Aneuploidy in Saccharomyces cerevisiae.

Dodgson SE, Kim S, Costanzo M, Baryshnikova A, Morse DL, Kaiser CA, Boone C, Amon A.

Genetics. 2016 Apr;202(4):1395-409. doi: 10.1534/genetics.115.185660. Epub 2016 Feb 2.

12.

Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.

Huynh AS, Estrella V, Stark VE, Cohen AS, Chen T, Casagni TJ, Josan JS, Lloyd MC, Johnson J, Kim J, Hruby VJ, Vagner J, Morse DL.

Mol Pharm. 2016 Feb 1;13(2):534-44. doi: 10.1021/acs.molpharmaceut.5b00760. Epub 2016 Jan 8.

13.

Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane.

Damaghi M, Tafreshi NK, Lloyd MC, Sprung R, Estrella V, Wojtkowiak JW, Morse DL, Koomen JM, Bui MM, Gatenby RA, Gillies RJ.

Nat Commun. 2015 Dec 10;6:8752. doi: 10.1038/ncomms9752.

14.

Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.

Cohen AS, Patek R, Enkemann SA, Johnson JO, Chen T, Toloza E, Vagner J, Morse DL.

Bioconjug Chem. 2016 Feb 17;27(2):427-38. doi: 10.1021/acs.bioconjchem.5b00516. Epub 2015 Oct 30.

15.

Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.

Tafreshi NK, Lloyd MC, Proemsey JB, Bui MM, Kim J, Gillies RJ, Morse DL.

Mol Imaging Biol. 2016 Apr;18(2):219-31. doi: 10.1007/s11307-015-0885-x.

16.

The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition.

Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse DL.

Front Immunol. 2014 Oct 20;5:429. doi: 10.3389/fimmu.2014.00429. eCollection 2014. Review.

17.

Integrating public health education in a public health practice setting: the experience of the School of Public Health, University at Albany and the New York State Department of Health.

Birkhead GS, Eidson M, Dewar D, Nasca P, Morse DL, Shah NR.

J Public Health Manag Pract. 2014 May-Jun;20(3):278-84. doi: 10.1097/PHH.0b013e31829a4d73.

PMID:
24667187
18.

Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy.

Foroutan P, Kreahling JM, Morse DL, Grove O, Lloyd MC, Reed D, Raghavan M, Altiok S, Martinez GV, Gillies RJ.

PLoS One. 2013 Dec 16;8(12):e82875. doi: 10.1371/journal.pone.0082875. eCollection 2013.

19.

Rapid screening of novel agents for combination therapy in sarcomas.

Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR.

Sarcoma. 2013;2013:365723. doi: 10.1155/2013/365723. Epub 2013 Oct 24.

20.

Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases.

Tafreshi NK, Lloyd MC, Bui MM, Gillies RJ, Morse DL.

Subcell Biochem. 2014;75:221-54. doi: 10.1007/978-94-007-7359-2_12. Review.

21.

Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors.

Alleti R, Vagner J, Dehigaspitiya DC, Moberg VE, Elshan NG, Tafreshi NK, Brabez N, Weber CS, Lynch RM, Hruby VJ, Gillies RJ, Morse DL, Mash EA.

Bioorg Med Chem. 2013 Sep 1;21(17):5029-38. doi: 10.1016/j.bmc.2013.06.052. Epub 2013 Jul 2.

22.

Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptor.

Barkey NM, Preihs C, Cornnell HH, Martinez G, Carie A, Vagner J, Xu L, Lloyd MC, Lynch VM, Hruby VJ, Sessler JL, Sill KN, Gillies RJ, Morse DL.

J Med Chem. 2013 Aug 22;56(16):6330-8. doi: 10.1021/jm4005576. Epub 2013 Aug 9.

23.

In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.

Tafreshi NK, Silva A, Estrella VC, McCardle TW, Chen T, Jeune-Smith Y, Lloyd MC, Enkemann SA, Smalley KS, Sondak VK, Vagner J, Morse DL.

Mol Pharm. 2013 Aug 5;10(8):3175-85. doi: 10.1021/mp400222j. Epub 2013 Jul 8.

24.

Molecular imaging of breast cancer lymph node metastasis.

Tafreshi NK, Gillies RJ, Morse DL.

Eur J Radiol. 2012 Sep;81 Suppl 1:S160-1. doi: 10.1016/S0720-048X(12)70067-0. No abstract available.

25.

The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study.

Rejniak KA, Estrella V, Chen T, Cohen AS, Lloyd MC, Morse DL.

Front Oncol. 2013 May 10;3:111. doi: 10.3389/fonc.2013.00111. eCollection 2013.

26.

Demonstration of a sucrose-derived contrast agent for magnetic resonance imaging of the GI tract.

Martinez GV, Navath S, Sewda K, Rao V, Foroutan P, Alleti R, Moberg VE, Ahad AM, Coppola D, Lloyd MC, Gillies RJ, Morse DL, Mash EA.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2061-4. doi: 10.1016/j.bmcl.2013.02.008. Epub 2013 Feb 13.

27.

Heterobivalent ligands target cell-surface receptor combinations in vivo.

Xu L, Josan JS, Vagner J, Caplan MR, Hruby VJ, Mash EA, Lynch RM, Morse DL, Gillies RJ.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21295-300. doi: 10.1073/pnas.1211762109. Epub 2012 Dec 10.

28.

Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Tafreshi NK, Huang X, Moberg VE, Barkey NM, Sondak VK, Tian H, Morse DL, Vagner J.

Bioconjug Chem. 2012 Dec 19;23(12):2451-9. doi: 10.1021/bc300549s. Epub 2012 Nov 27.

29.

Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Huynh AS, Chung WJ, Cho HI, Moberg VE, Celis E, Morse DL, Vagner J.

J Med Chem. 2012 Nov 26;55(22):9751-62. doi: 10.1021/jm301002f. Epub 2012 Nov 8.

30.

A national case-control study identifies human socio-economic status and activities as risk factors for tick-borne encephalitis in Poland.

Stefanoff P, Rosinska M, Samuels S, White DJ, Morse DL, Randolph SE.

PLoS One. 2012;7(9):e45511. doi: 10.1371/journal.pone.0045511. Epub 2012 Sep 19.

31.

Occupational exposure to body fluids among health care workers in Georgia.

Butsashvili M, Kamkamidze G, Kajaia M, Morse DL, Triner W, Dehovitz J, McNutt LA.

Occup Med (Lond). 2012 Dec;62(8):620-6. doi: 10.1093/occmed/kqs121. Epub 2012 Aug 6.

32.

Photoacoustic tomography and fluorescence molecular tomography: a comparative study based on indocyanine green.

Wang B, Zhao Q, Barkey NM, Morse DL, Jiang H.

Med Phys. 2012 May;39(5):2512-7. doi: 10.1118/1.3700401.

33.

Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes.

Tafreshi NK, Bui MM, Bishop K, Lloyd MC, Enkemann SA, Lopez AS, Abrahams D, Carter BW, Vagner J, Grobmyer SR, Gillies RJ, Morse DL.

Clin Cancer Res. 2012 Jan 1;18(1):207-19. doi: 10.1158/1078-0432.CCR-11-0238. Epub 2011 Oct 20. Erratum in: Clin Cancer Res. 2012 Mar 1;18(5):1483. Gobmyer, Stephen R [corrected to Grobmyer, Stephen R].

34.

Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Barkey NM, Tafreshi NK, Josan JS, De Silva CR, Sill KN, Hruby VJ, Gillies RJ, Morse DL, Vagner J.

J Med Chem. 2011 Dec 8;54(23):8078-84. doi: 10.1021/jm201226w. Epub 2011 Nov 10.

35.

A sucrose-derived scaffold for multimerization of bioactive peptides.

Rao V, Alleti R, Xu L, Tafreshi NK, Morse DL, Gillies RJ, Mash EA.

Bioorg Med Chem. 2011 Nov 1;19(21):6474-82. doi: 10.1016/j.bmc.2011.08.053. Epub 2011 Aug 27.

36.

Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells.

Huynh AS, Abrahams DF, Torres MS, Baldwin MK, Gillies RJ, Morse DL.

PLoS One. 2011;6(5):e20330. doi: 10.1371/journal.pone.0020330. Epub 2011 May 27.

37.

Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents.

Martinez GV, Zhang X, García-Martín ML, Morse DL, Woods M, Sherry AD, Gillies RJ.

NMR Biomed. 2011 Dec;24(10):1380-91. doi: 10.1002/nbm.1701. Epub 2011 May 23.

38.

Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State university, 2010.

Bednarczyk RA, Birkhead GS, Morse DL, Doleyres H, McNutt LA.

Vaccine. 2011 Apr 12;29(17):3138-43. doi: 10.1016/j.vaccine.2011.02.045. Epub 2011 Mar 4.

PMID:
21376797
39.

The promise of nanotechnology for solving clinical problems in breast cancer.

Grobmyer SR, Morse DL, Fletcher B, Gutwein LG, Sharma P, Krishna V, Frost SC, Moudgil BM, Brown SC.

J Surg Oncol. 2011 Mar 15;103(4):317-25. doi: 10.1002/jso.21698. Review.

PMID:
21337565
40.

A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes.

Tafreshi NK, Enkemann SA, Bui MM, Lloyd MC, Abrahams D, Huynh AS, Kim J, Grobmyer SR, Carter WB, Vagner J, Gillies RJ, Morse DL.

Cancer Res. 2011 Feb 1;71(3):1050-9. doi: 10.1158/0008-5472.CAN-10-3091. Epub 2010 Dec 17.

41.

Risk factors for relapse of visceral leishmaniasis in Georgia.

Kajaia M, Morse DL, Kamkamidze G, Butsashvili M, Chubabria G, Zenaishvili O, Kokaia N, McNutt LA.

Trop Med Int Health. 2011 Feb;16(2):186-92. doi: 10.1111/j.1365-3156.2010.02694.x. Epub 2010 Dec 8.

42.

Molecular and functional imaging of breast cancer.

Tafreshi NK, Kumar V, Morse DL, Gatenby RA.

Cancer Control. 2010 Jul;17(3):143-55. Review.

PMID:
20664511
43.

The biology underlying molecular imaging in oncology: from genome to anatome and back again.

Gillies RJ, Anderson AR, Gatenby RA, Morse DL.

Clin Radiol. 2010 Jul;65(7):517-21. doi: 10.1016/j.crad.2010.04.005.

44.

Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray.

Morse DL, Balagurunathan Y, Hostetter G, Trissal M, Tafreshi NK, Burke N, Lloyd M, Enkemann S, Coppola D, Hruby VJ, Gillies RJ, Han H.

Biochem Pharmacol. 2010 Sep 1;80(5):748-54. doi: 10.1016/j.bcp.2010.05.018. Epub 2010 May 25.

45.

Molecular imaging and targeted therapies.

Morse DL, Gillies RJ.

Biochem Pharmacol. 2010 Sep 1;80(5):731-8. doi: 10.1016/j.bcp.2010.04.011. Epub 2010 Apr 21. Review.

46.

Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors.

Xu L, Vagner J, Alleti R, Rao V, Jagadish B, Morse DL, Hruby VJ, Gillies RJ, Mash EA.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2489-92. doi: 10.1016/j.bmcl.2010.03.007. Epub 2010 Mar 4.

47.

Identification of pancreatic cancer-specific cell-surface markers for development of targeting ligands.

Morse DL, Hostetter G, Balagurunathan Y, Gillies RJ, Han H.

Methods Mol Biol. 2010;624:195-210. doi: 10.1007/978-1-60761-609-2_13.

48.

Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine.

Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL.

Vaccine. 2010 Jan 8;28(3):754-8. doi: 10.1016/j.vaccine.2009.10.075. Epub 2009 Nov 5.

PMID:
19896451
49.

Enhanced targeting with heterobivalent ligands.

Xu L, Vagner J, Josan J, Lynch RM, Morse DL, Baggett B, Han H, Mash EA, Hruby VJ, Gillies RJ.

Mol Cancer Ther. 2009 Aug;8(8):2356-65. doi: 10.1158/1535-7163.MCT-08-1183. Epub 2009 Aug 11.

50.

Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging.

Josan JS, Morse DL, Xu L, Trissal M, Baggett B, Davis P, Vagner J, Gillies RJ, Hruby VJ.

Org Lett. 2009 Jun 18;11(12):2479-82. doi: 10.1021/ol900200k.

Supplemental Content

Loading ...
Support Center